[1]王 伟,石 兵,王丽平.固肾祛湿化浊汤联合阿比特龙治疗去势抵抗性前列腺癌临床研究[J].陕西中医,2021,(2):200-203,208.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.016]
　WANG Wei,SHI Bing,WANG Liping.Castration-resistant prostate cancer treated by Gushen Qushi Huazhuo decoction combined with abiraterone[J].,2021,(2):200-203,208.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.016]
点击复制

固肾祛湿化浊汤联合阿比特龙治疗去势抵抗性前列腺癌临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年2期
页码:
200-203,208
栏目:
临床研究
出版日期:
2021-02-05

文章信息/Info

Title:
Castration-resistant prostate cancer treated by Gushen Qushi Huazhuo decoction combined with abiraterone
作者:
王 伟1; 石 兵1 ; 王丽平2
(1.南通市中医院泌尿外科,江苏 南通226001; 2.郑州大学药学院,河南 郑州450001)
Author(s):
WANG Wei; SHI Bing; WANG Liping
(Department of Urology,Nantong Hospital of Traditional Chinese Medicine,Nantong 226001,China)
关键词:
去势抵抗性前列腺癌;  固肾祛湿化浊汤;  阿比特龙;  前列腺特异性抗原;  睾酮;  尿流动力学
Keywords:
Castration-resistant prostate cancer;  Gushen Qushi Huazhuo decoction;  Abiraterone;  Prostate-specific antigen;  Testosterone;  Urodynamic parameters
分类号:
R 737.25
DOI:
DOI:10.3969/j.issn.1000-7369.2020.02.016
文献标志码:
A
摘要:
目的:研究固肾祛湿化浊汤与阿比特龙联合治疗去势抵抗性前列腺癌的临床疗效。方法:选取63例去势抵抗性前列腺癌(CRPC)患者纳入本次研究,采用随机数字表法将入选患者划分为对照组与治疗组,对照组给予阿比特龙治疗,治疗组在对照组疗法的同时给予固肾祛湿化浊汤治疗; 治疗3个周期后,评估两组患者实体瘤临床疗效、中医症候积分与中医证候疗效,统计两组患者3个周期中不良反应发生情况,观察治疗前、后两组患者血清标志物:前列腺特异性抗原(PSA)、睾酮,尿流动力学指标:最大尿流率(MFR)、剩余尿量(PVR)与生活质量Karnofsky(KPS)评分的变化情况。结果:治疗组实体瘤整体临床疗效水平优于对照组(P<0.05); 治疗组中医症候总有效率为96.43%,对照组为78.57%,治疗组中医证候总有效率与整体疗效水平均优于对照组(均P<0.05); 治疗后两组中医症候积分均较治疗前降低(均P<0.05),且治疗组低于对照组(P<0.05); 对照组不良反应发生率为35.71%,治疗组为21.43%,两组比较差异无统计学意义(P>0.05); 治疗后,两组患者PSA、睾酮、PVR均较前下降(均P<0.05),MFR、KPS评分均较前升高(均P<0.05),且治疗组患者PSA、睾酮、PVR均低于对照组(均P<0.05),MFR、KPS评分均高于对照组(均P<0.05)。结论:固肾祛湿化浊汤与阿比特龙联合治疗去势抵抗性前列腺癌可提高临床疗效与生活质量,降低血清标志物表达水平,改善患者尿流动力学指标,且用药方案安全。
Abstract:
Objective:To study the clinical efficacy and clinical indicators of the combination of Gushen Qushi Huazhuo decoction and abiraterone in the treatment of castration-resistant prostate cancer(CRPC).Methods:A total of 63 cases of CRPC patients were included in this study and divided into the control group and treatment group by using the random number table method.Patients in the control group were given abiraterone for treatment,while patients in the treatment group were give the Gushen Qushi Huazhuo decoction treatment on the basis of therapeutic method in the control group.After three treatment cycles,the clinical efficacy,traditional Chinese medicine(TCM)syndrome score and TCM syndrome effect of the two groups were evaluated in the two groups.The adverse reactions were analyzed within the three cycles of the two groups.Serum markers of prostate specific antigen(PSA)and testosterone,urine flow dynamic indexes of maximum urinary flow rate(MFR)and postvoid residual urine volume(PVR),and changes of Karnofsky performance score(KPS)were observed in patients of the two groups before and after treatment.Meanwhile,patients were followed up for at least 24 months to analyze the progression-free survival time(PFS)and overall survival(OS)time of the two groups.Results:The overall clinical efficacy of solid tumor in the treatment group was better than that in the control group(P<0.05).The total effective rate of TCM syndrome in the treatment group was 96.43%,while that in the control group was 78.57%.The total effective rate and overall efficacy of TCM syndrome in the treatment group were both better than that in the control group(all P<0.05).After treatment,the TCM syndrome scores of both groups were lower than that before treatment(all P<0.05),and the treatment group had a lower score than that of the control group(all P<0.05).The incidence of adverse reactions was 35.71% in the control group and 21.43% in the treatment group,and there was no statistical difference between the two groups(P>0.05).After treatment,PSA,testosterone and PVR of patients in both groups decreased compared with those before treatment(all P<0.05),while MFR and KPS scores increased than those before treatment(P<0.05).Besides,PSA,testosterone and PVR of patients in the treatment group were lower than those in the control group(all P<0.05),while MFR and KPS scores were higher than those in the control group(all P<0.05).Conclusion:The combination of Gushen Qushi Huazhuo decoction and abiraterone in the treatment of CRPC can improve the clinical efficacy and quality of life,reduce the expression level of serum markers,and improve the urodynamic parameters.

参考文献/References:

[1] Emamekhoo H,Barata PC,Edwin NC,et al.Evaluation of response to enzalutamide consecutively after abiraterone acetate/prednisone failure in patients with metastatic castration-resistant prostate cancer[J].Clin Genitourin Cancer,2018,16(6):429-436.
[2] Roviello G,Petrioli R,Bonetta A,et al.Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone[J].Invest New Drugs,2018,36(6):1110-1115.
[3] 邵亚军,雷霆宇,邵林海.直肠B超会阴前列腺12点穿刺术对前列腺特异性抗原水平为4～10 ng/ml患者前列腺癌诊断价值[J].陕西医学杂志,2020,49(4):450-452,513.
[4] 刘 浩,彭 倩,何阳科,等.阿比特龙联合强的松治疗去势抵抗性前列腺癌的临床观察[J].实用医院临床杂志,2018,15(4):49-51.
[5] Payne H,Jamieson L,Prentice M,et al.Preferences for toxicity monitoring of patients on abiraterone acetate plus prednisone[J].Clin Oncol(R Coll Radiol),2018,30(10):674-675.
[6] Attard G,Borre M,Gurney H,et al.Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment[J].J Clin Oncol,2018,36(25):2639-2646.
[7] 龙振河,崔 娟.阿比特龙与多西他赛治疗转移性去势抵抗性前列腺癌的临床观察[J].蛇志,2020,32(2):185-187.
[8] 楼正达,骆俊峰,王伟强,等.阿比特龙治疗转移性去势抵抗性前列腺癌临床疗效及安全性[J].浙江中西医结合杂志,2019,29(12):1007-1009.
[9] 中华医学会泌尿外科学分会,中国前列腺癌联盟.中国前列腺癌药物去势治疗专家共识[J].中华泌尿外科杂志,2016,37(7):481-484.
[10] 中国抗癌协会泌尿男生殖系肿瘤专业委员会.2018版转移性前列腺癌诊治中国专家共识[J].中华外科杂志,2018,56(9):646-652.
[11] 国家食品药品监督管理总局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:198-199.
[12] Mor V,Laliberte L,Morris JN,et al.The karnofsky performance status scale:An examination of its reliability and validity in a research setting[J].Cancer,1984,53(9):2002-2007.
[13] 中华医学会泌尿外科学分会,中国前列腺癌联盟.转移性前列腺癌化疗中国专家共识(2019版)[J].中华泌尿外科杂志,2019,40(10):721-725.
[14] 吴 波,周东言,杨 波.阿比特龙辅助DP化疗治疗去势抵抗性前列腺癌的疗效观察[J].中国医师杂志,2019,21(5):779-781.
[15] 杜 鸿,李 俊,邱明星.阿比特龙治疗去势抵抗性前列腺癌安全性分析[J].实用医院临床杂志,2019,16(3):33-35.
[16] 樊连城,董柏君,迟辰斐,等.阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌的疗效及预后因素分析[J].上海交通大学学报:医学版,2017,37(11):1482-1488.
[17] 李明林.健脾益肾方对前列腺癌患者手术去势后性激素,PSA的影响研究[J].陕西中医,2018,39(3):354-357.
[18] 陈 红,王 凯.前列消癥汤辅助治疗前列腺癌的临床疗效[J].癌症进展,2020,18(14):1489-1491.

备注/Memo

备注/Memo:
基金项目:河南省医学科技攻关项目(2011020085)
更新日期/Last Update: 2021-01-28